Cargando…
Long-term outcomes of ranibizumab vs. aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
To evaluate the long-term outcomes of ranibizumab (RBZ) vs. aflibercept (AFL) in treatment-naïve eyes with typical neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV). This multicenter, retrospective, matched-cohort analysis was conducted on data up to 4 ...
Autores principales: | Jin, Ki Won, Kim, Jae Hui, Park, Jun Young, Park, Sang Jun, Park, Kyu Hyung, Lee, Joo Yong, Woo, Se Joon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285484/ https://www.ncbi.nlm.nih.gov/pubmed/34272419 http://dx.doi.org/10.1038/s41598-021-93899-x |
Ejemplares similares
-
Four-Year Outcome of Aflibercept for Neovascular Age-Related Macular Degeneration and polypoidal choroidal vasculopathy
por: Nishikawa, Keiichi, et al.
Publicado: (2019) -
Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
por: Matsumiya, Wataru, et al.
Publicado: (2011) -
Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013) -
Intravitreal aflibercept for active polypoidal choroidal vasculopathy without active polyps
por: Lee, Sang Eun, et al.
Publicado: (2019) -
Polypoidal choroidal vasculopathy in Caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response
por: Hatz, Katja, et al.
Publicado: (2014)